A series of methylenedioxybenzene compounds were synthesized and found to have hepatoprotective effects in chemical-induced hepatotoxicity models. The purpose of the present study was to investigate the anti-fibrotic effects of a synthetic methylenedioxybenzene compound, CW209292, using the dimethylnitrosamine (DMN)-induced chronic liver injury model in rats. Liver injuries were induced in Sprague Dawley rats by injection of DMN (intraperitoneally, 10 microl/kg) 3 times per week for 4 weeks. The rats were treated with CW209292 (per os, 25 or 75 mg/kg/d) for 4 weeks. Treatment of rats with DMN for 4 weeks resulted in significant decreases in serum albumin levels, whereas concomitant treatment with CW209292 prevented these decreases. CW209292 treatment also shortened prothrombin time prolonged by DMN, providing evidence that the agent was active in preserving liver function against DMN insult. DMN treatment caused marked increases in plasma bilirubin, aspartate aminotransferase (AST), alanine transaminase (ALT), and hyaluronic acid levels; CW209292 treatment reversed these increases. CW209292 also significantly reduced hepatic hydroxyproline content as well as hepatic fibrosis and inflammation in histological examination. Additionally, immunochemically detectable hepatic collagen type IV and alpha-smooth muscle actin levels were decreased by CW209292 treatment. Proliferation of hepatic stellate cells isolated from DMN-treated rats was inhibited by CW209292. Furthermore, tumor growth factor (TGF)-beta1 mRNA expression was increased in DMN-treated rats, whereas CW209292 treatment prevented these increases. These results suggest that CW209292 exhibits anti-fibrotic effects in Sprague Dawley rats with DMN-induced hepatic fibrosis by blocking the mRNA expression of TGF-beta1 and subsequent inhibition of the proliferation of hepatic stellate cells.

01 Dec 2005·Tetrahedron

Combining enabling techniques in organic synthesis: solid-phase-assisted catalysis under microwave conditions using a stable Pd(II)-precatalyst

Author: Kamal M. Dawood ; Andreas Kirschning

The catalytic activity of a 2-pyridinealdoxime-based Pd(II)-complex covalently anchored via the oxime moiety to a glass/polymer composite material was evaluated in Suzuki-Miyaura cross-coupling reactions of aryl and heteroaryl halides, including aryl chlorides, with aryl and heteroaryl boronic acids both under thermal as well as microwave irradiation conditions in water.The stability and reusability of this Pd-precatalyst are also studied.

01 Apr 1930·Journal of the American Chemical Society

SYNTHESIS OF THIAZOLES CONTAINING PHENOL AND CATECHOL GROUPS. II

Author: Suter, C. M. ; Johnson, Treat B.

cf. C. A. 23, 3470.New thiazoles containing aromatic groups in positions 2 and 4 of the thiazole cycle have been prepared as follows: 2-[p-Methoxyphenyl], from bromoacetal and thioanisamide (I), b₆, 156-8°, m. 12-5° (110 salt, m. 167-9°;73% yield); p-[hydroxyphenyl], by demethylation with 48% HBr, m. 163-5° (HCl salt, crystallizes with 0.5 mol.EtOH, m. 178-80°); 2-[p-methoxyphenyl]-4-methyl, from ClCH₂Ac and I, b₇ 168°, m. 57° (HCl salt, crystals with 0.5 mol.EtOH, m. 130-2°); 90% yield; p-HO derivative m. 220-1° (HCl salt, m. 250-3°; 2-[p-methoxyphenyl]-4-[3,4-dihydroxyphenyl], crystals with 2 mols.H₂O, m. 154-5° (HCl salt, m. 206-8°; p-HO derivative, crystals with 2 mols.H₂O, m. 212-3°; 2-[3,4-dihydroxyphenyl]-4-[3,4-dihydroxyphenyl], crystals with 1 mol.H₂O, m. 207°, in 80% yield from chloroacetopyrocutechol and 3,4-dihydroxythiobenzamide, m. 153-4°; with bromoacetal there results the 2-[3,4-dihydroxyphenyl] derivative, m. 181° (HCl salt, m. 215-8°); ClCH₂Ac gives the 2-[3,4-dihydroxyphenyl]-4-methyl derivative, whose HCl salt m. 250°; bromoacetal and piperonylthioamide, m. 180° (81% yield), give the 2-[3,4-methylenedioxyphenyl] derivative, m. 84-5°; (HCl salt, m. 216°); 2-[3,4-methylenedioxyphenyl]-4-methyl, m. 94-5° (91% yield) (HCl salt, crystals with 1 mol.EtOH), the 4-[3,4-dihydroxyphenyl]-2-[3,4-methylenedioxyphenyl] derivative, crystals with 2 H₂O, m. 135°, or anhyd, m. 185° (99% yield) (HCl salt, m. 212-6°).The pharmacol. behavior of these compounds is briefly discussed.

100 Deals associated with CW-209292

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Fibrosis, Liver	Preclinical	South Korea	Seoul National University	02 Jan 2009
Fibrosis, Liver	Preclinical	South Korea	JW PHARMACEUTICAL Corp.	02 Jan 2009
Hepatitis B	Preclinical	South Korea	JW PHARMACEUTICAL Corp.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

CW-209292

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation